New diabetes drug enters testing against popular treatment
NCT ID NCT07187856
Summary
This study is testing a new injectable medication called PG-102 for people with type 2 diabetes. Researchers will compare PG-102 against a placebo (inactive treatment) and an existing diabetes drug called semaglutide over 24 weeks. The main goals are to see if PG-102 safely lowers blood sugar levels and affects body weight in 80 adult participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emeritus Research
Camberwell, Victoria, 3124, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.